Oncology

With new strategic financing and powerhouse board appointments, 4D Path is accelerating its novel AI platform that predicts cancer treatment success from a single slide.

UK biotech Cytospire Therapeutics secures major funding to push its safer, more selective gamma delta T-cell engager into clinical trials for solid tumors.

At the elite FiRe 2026 conference, Pattern Computer plans to unveil a 'hallucination-free' AI, promising a new era of scientific discovery and trust.

New FDA-registered system from Clarapath offers labs a flexible, lower-cost entry into automation, targeting a critical bottleneck in pathology workflows.

A major investment in natural killer cell immunotherapy aims to revolutionize treatment for Canada's most fatal women's cancer after decades of stagnation.

A strategic investment from FreeMind Investments and Daewoong Pharma validates General Proximity's novel platform for next-gen induced proximity medicines.

Standard skin checks often miss deadly melanomas. An Arizona dermatologist sounds the alarm on a critical detection gap and a tool that could save lives.

The clinical-stage biotech adds seasoned veterans from Eli Lilly and Iovance to accelerate its promising DNA Damage Response pipeline toward commercialization.

Spanish CDMO ROIS acquires a major Phoenix facility from Bristol Myers Squibb, securing US drug supply chains and expanding its global footprint.

A $1M grant funds research into an ultra-rare cancer's defense mechanism, offering new hope against a disease with a grim 10% survival rate.

With cash burn rising, Summit Therapeutics races toward a November FDA decision on its novel cancer drug ivonescimab and a major data reveal at ASCO.

New pre-clinical data shows engineered immune cells (iMacrophages) can effectively target and destroy ovarian tumors, offering hope for a new treatment era.

New research challenges long-held beliefs, revealing a high-risk subset in "safe" tumors and a surprising link between body weight and cancer recurrence.

Swedish firm Navinci launches its Omni kit, targeting the spatial interactomics market with a new tool to visualize protein networks directly in tissue.

KCIC's 2025 report shows asbestos filings hitting a new peak, driven by a dramatic rise in talc-related lawsuits and massive jury awards.

With a fourfold revenue jump, China's Yangtze River Pharmaceutical Group isn't just selling drugs; it's exporting a new model of global trust and quality.

Massive Bio and OpenAI launch a groundbreaking AI initiative to automate patient matching for clinical trials, aiming to boost health equity and speed up research.

A new federal initiative aims to eliminate paper forms in clinics, giving patients control over their health data with a simple QR code. Here's how it works.

Formerly LA Cancer Network, Oncura Health's new Los Alamitos clinic brings advanced, physician-led oncology services to a competitive Orange County market.

A new collaboration aims to merge drugs with AI-driven apps, creating a novel class of therapy that could revolutionize treatment, starting with rare cancers.